폐경전 여성에서 항암 치료 이후 유방암 환자와 일반인의 골밀도 비교 = Comparison of Bone Mineral Density with Breast Cancer Patients after Chemotherapy and Normal Control in Premenopausal Women

다국어 초록 (Multilingual Abstract)

Objectives: There is a lack of data on bone loss in premenopausal patients with breast cancer after chemotherapy in Korea. In this study, we compared the bone mineral density of breast cancer patients after chemotherapy with normal control.
Materials and Methods: We used the data from the fourth Korea National Health and Nutrition Examination Survey (KNHNES) as normal control, and 119 women were enrolled who had surgery and chemotherapy due to breast cancer. They were under the age of 50 and premenopausal state according to their FSH level. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry.
Results: T-score at Lumbar spine BMD was not different between breast cancer group and control group (0.16±0.98 vs 0.08±1.00, P=0.451). And neither did T-score at femoral neck (-0.18±1.09 vs -0.27±0.95, P=0.419). T-score at total hip BMD was significantly different between two groups (0.26±0.97 vs 0.64±0.91, P<0.001). After adjustment of age and body mass index, the significance still remained (P<0.001 and P=0.001, respectively). The prevalence of bone loss (osteopenia and osteoporosis) at total hip was higher in breast cancer group than control group (10.1% vs 5.5%, P=0.012)Conclusions: The patients with breast cancer needs to evaluate the bone mineral density at total hip even if they are premenopausal states.

참고문헌 (Reference)

• 1 안세현, "폐경이후 한국인 유방암 환자의 골밀도와 유방암 발병과의 상관관계" 한국유방암학회 9 (9): 330-336, 2006
• 2 Hershman DL, "Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer" 26 : 4739-4745, 2008
• 3 Hadji P, "The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer" 45 : 3205-3212, 2009
• 4 Wang TM, "Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide" 127 : 93-99, 1986
• 5 Ahn SH, "Relation between body size and body mass index and breast cancer by menopausal status in Korea" 31 : 72-81, 1999
• 6 Goldhirsch A, "Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007" 18 : 1133-1144, 2007
• 7 Hershman D, "Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer" 6 : 277-284, 2004
• 8 Shapiro CL, "Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer" 19 : 3306-3311, 2001
• 9 Pfeilschifter J, "Osteoporosis due to cancer treatment: pathogenesis and management" 18 : 1570-1593, 2000
• 10 "Nationwide Korean Breast Cancer Data of 2004 Using Breast Cancer Registration Program" 9 : 151-161, 2006
• 11 Saarto T, "Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients" 15 : 1341-1347, 1997
• 12 van der Klift M, "Bone mineral density and the risk of breast cancer: the Rotterdam Study" 32 : 211-216, 2003
• 13 Bruning PF, "Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer" 61 : 308-310, 1990
• 14 Kother M, "Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide" 6 : 219-221, 1992
• 15 Kanis JA, "A high incidence of vertebral fracture in women with breast cancer" 79 : 1179-1181, 1999